Your browser is no longer supported. Please, upgrade your browser.
XLRN Acceleron Pharma Inc. weekly Stock Chart
XLRN [NASD]
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own13.90% Shs Outstand53.50M Perf Week3.15%
Market Cap2.14B Forward P/E- EPS next Y-1.48 Insider Trans9.81% Shs Float45.04M Perf Month-2.66%
Income-130.70M PEG- EPS next Q-0.30 Inst Own94.00% Short Float10.91% Perf Quarter-11.74%
Sales13.50M P/S158.20 EPS this Y3.50% Inst Trans10.04% Short Ratio16.70 Perf Half Y-7.93%
Book/sh9.99 P/B4.00 EPS next Y34.20% ROA-33.40% Target Price60.17 Perf Year8.45%
Cash/sh8.18 P/C4.88 EPS next 5Y- ROE-35.90% 52W Range32.53 - 59.59 Perf YTD-8.34%
Dividend- P/FCF- EPS past 5Y9.00% ROI-42.60% 52W High-31.65% Beta1.18
Dividend %- Quick Ratio19.30 Sales past 5Y-24.60% Gross Margin- 52W Low25.21% ATR1.48
Employees173 Current Ratio19.30 Sales Q/Q-12.50% Oper. Margin- RSI (14)52.90 Volatility3.72% 3.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.20% Profit Margin- Rel Volume0.66 Prev Close39.92
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume294.39K Price40.73
Recom2.10 SMA201.91% SMA50-0.52% SMA200-11.77% Volume102,231 Change2.03%
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Jun-13-17Downgrade Oppenheimer Outperform → Perform
May-17-17Initiated Goldman Sell $20
Mar-14-17Initiated JP Morgan Neutral
Mar-09-17Initiated UBS Buy $36
Mar-02-17Upgrade Citigroup Neutral → Buy
Jun-14-19 02:41PM  Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis Simply Wall St.
Jun-13-19 12:27PM  Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
Jun-10-19 07:00AM  Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis Business Wire
Jun-06-19 04:56PM  Celgene & Acceleron's BLA for Luspatercept Accepted by FDA Zacks
Jun-05-19 09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
Jun-04-19 04:24PM  Here's Another Checkmark For Bristol's Looming Celgene Takeover Investor's Business Daily
07:30AM  Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia Business Wire
May-28-19 10:11AM  Geron Stock Up More Than 50% in 2019 So Far: Here's Why Zacks
May-14-19 07:00AM  Acceleron to Present at the UBS Global Healthcare Conference Business Wire
May-09-19 07:15PM  Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:09PM  Acceleron: 1Q Earnings Snapshot Associated Press
04:05PM  Acceleron Reports First Quarter 2019 Operating and Financial Results Business Wire
May-08-19 10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
07:41AM  5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility Zacks
May-07-19 10:38AM  Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings? Zacks
05:53AM  Telenav (TNAV) to Report Q3 Earnings: What's in the Offing? Zacks
May-06-19 05:07AM  Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings? Zacks
May-01-19 07:00AM  Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019 Business Wire
Apr-29-19 09:58PM  Heres What Hedge Funds Think About Acceleron Pharma Inc (XLRN) Insider Monkey
Apr-26-19 01:44PM  Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales Zacks
07:30AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia Business Wire
Apr-15-19 02:03PM  If You Had Bought Acceleron Pharma (NASDAQ:XLRN) Shares Three Years Ago You'd Have Made 36% Simply Wall St.
Apr-12-19 01:03AM  Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Apr-08-19 06:11PM  Celgene & Acceleron Submit BLA for Luspatercept to the FDA Zacks
Apr-05-19 04:01PM  Acceleron Announces Departure of Chief Medical Officer Business Wire
09:28AM  Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA Business Wire
07:48AM  The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership Benzinga
Mar-28-19 07:10AM  Factors of Influence in 2019, Key Indicators and Opportunity within The Ultimate Software Group, New Mountain Finance, Denny's, World Fuel Services, Agree Realty, and Acceleron Pharma New Research Emphasizes Economic Growth GlobeNewswire
Mar-05-19 07:00AM  Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease Business Wire
Mar-01-19 12:32PM  Acceleron Pharma Inc. (NASDAQ:XLRN): The Best Of Both Worlds Simply Wall St.
Feb-28-19 02:48AM  Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-27-19 04:05PM  Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Business Wire
Feb-26-19 04:01PM  Acceleron Pharma Is Ready to Rally Ahead of Earnings TheStreet.com +6.79%
Feb-20-19 01:16PM  Is Acceleron Pharma a Buy? Motley Fool
10:31AM  Earnings Preview: Acceleron Pharma (XLRN) Q4 Earnings Expected to Decline Zacks
Feb-19-19 07:00AM  Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019 Business Wire
Feb-13-19 07:00AM  Acceleron to Present at Two Upcoming Healthcare Investor Conferences Business Wire
Jan-31-19 11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Jan-29-19 10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-24-19 12:58PM  Celgene Buys More of This Biotech Stock Barrons.com
Jan-22-19 07:30AM  Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-16-19 07:00AM  Acceleron Announces Pricing of Public Offering of Common Stock Business Wire
Jan-14-19 04:04PM  Acceleron Announces Proposed Public Offering of Common Stock Business Wire
Jan-10-19 07:00AM  Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood Business Wire
Jan-08-19 05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
02:39PM  Here's Why Acceleron Pharma Fell 17.7% in December Motley Fool
Jan-02-19 07:00AM  Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-18 05:07PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Dec-21-18 09:00AM  How Financially Strong Is Acceleron Pharma Inc. (NASDAQ:XLRN)? Simply Wall St.
Dec-12-18 03:10AM  Is Acceleron Pharma Inc (XLRN) A Good Stock To Buy? Insider Monkey
Dec-05-18 04:30PM  Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for Best of ASH by the American Society of Hematology Business Wire
Dec-03-18 06:09PM  Celgene (CELG) Announces Various Cancer Data at ASH 2018 Zacks
07:30AM  Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-01-18 05:00PM  Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018 Business Wire
07:03AM  Top Biotech Stocks to Watch at ASH 2018 Motley Fool
Nov-28-18 07:00AM  Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease Business Wire
Nov-27-18 07:00AM  Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting Business Wire
Nov-26-18 07:00AM  Acceleron to Participate in Two Upcoming Healthcare Investor Conferences Business Wire
Nov-19-18 08:46PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-07-18 09:16AM  3 Cancer Stocks to Watch in December Motley Fool
07:00AM  Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session Business Wire
Nov-03-18 02:16PM  Edited Transcript of XLRN earnings conference call or presentation 30-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-01-18 09:01AM  Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting Business Wire
Oct-30-18 05:25PM  Acceleron Pharma (XLRN) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:20PM  Acceleron: 3Q Earnings Snapshot Associated Press
04:05PM  Acceleron Reports Third Quarter 2018 Operating and Financial Results Business Wire
Oct-24-18 07:20AM  Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-23-18 07:00AM  Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018 Business Wire
Oct-16-18 07:00AM  Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City Business Wire +6.56%
Oct-04-18 08:51AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Sep-27-18 07:00AM  Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society Business Wire
Sep-20-18 08:00AM  Today's Research Reports on Trending Tickers: Acceleron Pharma and Tesaro ACCESSWIRE
Sep-18-18 02:44PM  Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential Benzinga
Sep-04-18 03:17PM  Here's Why Acceleron Pharma Rose 24% in August Motley Fool
Aug-14-18 07:34PM  Edited Transcript of XLRN earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-18 04:17PM  Could Biotech Giant Celgene Join Tesla In The Private Markets? Investor's Business Daily
Aug-04-18 01:11PM  Here's Why Acceleron Pharma Inc. Lost 10.2% in July Motley Fool
Aug-03-18 07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga
Aug-02-18 06:25PM  Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:21PM  Acceleron: 2Q Earnings Snapshot Associated Press
04:05PM  Acceleron Reports Second Quarter 2018 Operating and Financial Results Business Wire
07:53AM  Acceleron Pharma Q2 Earnings Preview Benzinga
Jul-26-18 07:00AM  Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018 Business Wire
Jul-18-18 07:15AM  Free Pre-Market Technical Recap on Genesis Healthcare and Three Additional Healthcare Stocks ACCESSWIRE
Jul-13-18 12:45PM  Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target Benzinga
Jul-12-18 07:00AM  Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy Business Wire
Jul-11-18 09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks
Jul-10-18 02:50PM  Celgene, Acceleron Report Positive Data on Thalassemia Drug Zacks
11:52AM  Upbeat Celgene Data Not Enough to Lift Biotech Sector Barrons.com
08:11AM  Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage Benzinga
Jul-09-18 06:13PM  [$$] Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results The Wall Street Journal
05:13PM  Celgene, Acceleron shares rise on blood-disorder drug study MarketWatch
04:52PM  Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia Business Wire
Jul-05-18 04:30PM  Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer Business Wire
Jul-02-18 08:10AM  Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals ACCESSWIRE
Jun-30-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
07:16AM  Celgene Investors Breathe a Sigh of Relief After Acceleron's Success Motley Fool
Jun-29-18 05:00PM  Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment Investor's Business Daily +42.79%
02:54PM  Celgene's Luspatercept Meets Primary Endpoint in the Study Zacks
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zakrzewski Joseph SDirectorJun 14Buy38.055,000190,25012,750Jun 17 06:08 PM
Quisel John DEVP, CBO and SecretaryApr 09Sale44.643,622161,67153,834Apr 11 04:58 PM
Kumar RavindraSVP & Chief Scientific OfficerApr 09Sale44.643,622161,67190,375Apr 11 04:58 PM
Dable Habib JCEO and PresidentApr 09Sale44.607,460332,74876,508Apr 11 04:58 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale44.6212,000535,40530,279Apr 11 04:58 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 02Sale48.0264831,11742,279Apr 04 06:07 PM
CELGENE CORP /DE/10% OwnerJan 18Buy43.00706,20630,366,8586,824,685Jan 22 05:00 PM
Dable Habib JCEO and PresidentJan 03Sale43.411,95784,96166,268Jan 04 06:34 PM
Quisel John DEVP, CBO and SecretaryJan 02Sale42.835,942254,49052,656Jan 04 06:35 PM
Kumar RavindraSVP & Chief Scientific OfficerJan 02Sale42.945,788248,54690,147Jan 04 06:36 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale42.805,712244,49438,227Jan 04 06:34 PM
Dable Habib JCEO and PresidentDec 04Sale52.9912,675671,61068,225Dec 06 04:22 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerAug 30Option Exercise27.9712,500349,62556,439Aug 31 07:00 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerAug 30Sale54.0012,500675,00043,939Aug 31 07:00 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJun 29Option Exercise24.1125,000602,75068,939Jul 03 02:32 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJun 29Sale48.0025,0001,200,00043,939Jul 03 02:32 PM